AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03715543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection of the Greater Splanchnic Nerve
Description: Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated.
Study NCT04612088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Dissonance
Description: A blood sample will be taken before the first take of the multivitamins and at the end of the intervention to measure: Hemoglobin, Calcium, Phosphorous, Iron, Copper, Zinc, Vitamin D, and Folate.~During the three months of the intervention, the intervention group will receive one psycho-educative session and five Cognitive Dissonance sessions.~Several tests will be applied to the patients at the beginning of the program and after the sessions to measure: patient knowledge and adherence to the multivitamin, self-efficacy, self-care, and Psycho-pathological symptoms.~The No intervention group on the wait list will receive the five Cognitive Dissonance sessions after the three months of the study.
Study NCT00843986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: Premix bag
Study NCT00843986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Premix bag
Study NCT02032524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase Alfa
Description: Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
Study NCT01901328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945
Study NCT01901328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03191786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab will be administered via IV infusion once every three weeks (QW3).
Study NCT03191786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
Study NCT03191786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered per relevant local guidelines and SmPC management.
Study NCT01719575 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Motilitone
Study NCT01719575 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT04188158 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: CAPECITABINE AND OXALIPLATIN
Description: Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
Study NCT04188158 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAPECITABINE AND OXALIPLATIN
Description: Intervention Group: Neoadjuvant chemotherapy ( 3 cycles Capecitabine and oxaliplatin) + surgery + adjuvant chemotherapy (5 cycles Capecitabine and oxaliplatin)
Study NCT01804855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: W82GO
Description: MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
Study NCT01791751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomifene Citrate
Description: Clomiphene citrate 100 mg daily for 5 days
Study NCT00835263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: 200 mg Tablet
Study NCT00835263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: 200 mg Tablet
Study NCT04504617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education intervention to enhance complementary feeding practices
Description: The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
Study NCT03620682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching sessions
Description: Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
Study NCT03620682 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile applications
Description: Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
Study NCT04504617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education intervention to enhance complementary feeding practices
Description: The intervention consist of a six-week nutrition education intervention developed following the DESIGN procedure and the Socio-Cognitive Theory. The intervention consisted of six three-hour weekly sessions that covered topics such as 1) importance and benefits of exclusive and continuing breastfeeding; 2) nutrition for lactating mothers; 3) importance and benefits of complementary feeding practices; 4) risks for starting complementary feeding too early or too late; 5) complementary feeding practices for each age group (6-8, 9-11, and 12-24); 6) importance and benefits of dietary diversity; 7) importance of animal-source foods; 8) importance and benefits of following water, sanitation, and hygiene practices; 9) food safety practices when preparing meals; and 10) the recommended hand-washing protocol. Each lesson was designed to provide a lecture, a discussion using counseling cards, a cooking demonstration with tasting session, and key messages.
Study NCT03637764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT01804855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone application
Description: Behavior change smartphone application for adolescents aiming to reduce obesity
Study NCT03019055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 0: 2.5 x10\^5 CAR-20/19-T cells/kg (starting dose level)
Study NCT03019055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 1: 7.5 x10\^5 CAR-20/19-T cells/kg
Study NCT00634322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucarpidase
Description: IV dose based on weight, two doses given for 5 minutes, 24 hours apart
Study NCT00634322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: IV or po given every 6 hours
Study NCT03019055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1 Dose Level 2: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b Expansion Dose Level: 2.5 x 10\^6 cells/kg (single infusion)
Study NCT03019055 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
Description: CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.
Study NCT00344370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg QD
Study NCT00344370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg
Study NCT03160144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open lung approach
Study NCT01024244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered po BID, prior to morning and evening meals for 12 weeks.
Study NCT02043860 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow Irradiation
Description: Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
Study NCT01024244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599506
Description: Administered po for 12 weeks
Study NCT03637764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study NCT02043860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Transplant
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
Study NCT02043860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Subjects will receive standard melphalan 200mg/m\^2 (100mg/m\^2 day-2 and day-1) conditioning therapy prior to transplant.
Study NCT02043860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm\^3 over period of 3 days.
Study NCT02318979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otto Bock prosthesis
Description: Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
Study NCT01495819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5cc's of saline give at least once.
Study NCT01495819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
Study NCT03831139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIM&SARA
Study NCT01198964 — intervention group
Intervention type: PROCEDURE
Intervention: Low-level cortical stimulation
Description: A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
Study NCT02017444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD4017
Study NCT02318979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur prosthesis
Description: Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
Study NCT02318979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freedom Innovations prosthesis
Description: Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
Study NCT02017444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo (matched to AZD4017 arm)
Study NCT04577768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS 2 mA
Description: anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 2 mA
Study NCT04577768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS 1.5 mA
Description: anodal high definition transcranial direct current stimulation of the right primary motor cortex with an intensity of 1.5 mA
Study NCT02037074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6308
Description: Arms 1, 2, 3
Study NCT02037074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Arm 4
Study NCT01461837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD34 selected T-cell depleted allogeneic SCT
Description: Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
Study NCT03795909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）
Study NCT03795909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）
Study NCT03795909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
Study NCT03795909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
Study NCT01104012 — intervention group
Intervention type: BIOLOGICAL
Intervention: Classification as asthmatic or rhinitis only via proteomic analysis
Description: Proteomic profiles are established for each patient using plasma and serum samples
Study NCT01104012 — intervention group
Intervention type: BIOLOGICAL
Intervention: Classification as asthmatic or rhinitis only according to a metacholine test
Description: A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
Study NCT03451968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: amino acid tracer injection for metabolism analysis
Description: the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc).
Study NCT03451968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amino acid tracer injection for metabolism analysis
Description: the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc).
Study NCT01824004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Study NCT03277274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-954
Description: TAK-954 intravenous infusion.
Study NCT04577768 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD-tDCS sham
Description: sham stimulation of the right primary motor cortex
Study NCT03787758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718
Study NCT02158507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Veliparib + Lapatinib
Description: Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
Study NCT03739554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYC065
Description: intravenous infusion
Study NCT03739554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: oral capsule
Study NCT02562885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic pulses
Description: Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB.
Study NCT01373229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Plerixafor (+ Rituximab)
Description: 1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression.
Study NCT03413358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sheng Bai oral liquid
Description: Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses
Study NCT01089595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Nilotinib 400 mg po bid
Study NCT01089595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib with Imatinib
Description: Nilotinib 400 mg po BID Imatinib 400 mg po daily
Study NCT03413358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based two medicine (carboplatin / cisplatin) .
Description: Using Platinum-based two medicine (carboplatin / cisplatin)
Study NCT01987544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergometer Training
Study NCT01987544 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergometer Training
Study NCT01987544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivation
Study NCT02874898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Imaginal Exposure
Description: Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
Study NCT02807090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Stabilization Exercise
Description: There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
Study NCT02807090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circular dance
Description: There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.